Abstract 64P
Background
Tumor associated macrophages (TAMs) are highly abundant immune cells present within the microenvironment of multiple tumor types. TAMs with a type 2 (M2)-like phenotype generally associate with poor prognosis and resistance against immunotherapy. In fact, we observed high frequencies of M2-like TAMs relative to those of CD8+ T cells according to gene expression analyses in multiple tumor types. In this study, we aim to engineer CD8+ T cells that resist M2-like macrophage-mediated suppression.
Methods
First, we have set up an in vitro co-culture model of human autologous M2-like macrophages and CD8+ T cells that yields T cell suppression. To this end, we have polarized in vitro monocytes from healthy donors into M2-like macrophages using a cytokine cocktail, after which we have optimized critical parameters, such as type of T cell stimulation, co-culture duration and the ratio between the two cell types.
Results
With this model, we have demonstrated that M2-like macrophages from multiple donors, when co-cultured with anti-CD3/CD28 antibody-stimulated autologous CD8+ T cells for 6 days, suppressed T cell proliferation by 50%. In a second step, we have adapted this model to a CRISPR-Cas9 gene editing-based approach: single guide RNA lentiviral infection with Cas9 electroporation (SLICE). We have successfully performed single gene editing, and are currently editing CD8+ T cells with gene libraries targeting kinases.
Conclusions
Taken together, we present a robust in vitro model of M2-like macrophage-mediated suppression of CD8+ T cells which enables the identification of genes that contribute to suppression-resistant CD8+ T cells. The making of such synthetic T cells is anticipated to aid the anti-tumor efficacy of adoptive T cell therapy.
Legal entity responsible for the study
Erasmus MC.
Funding
KWF Kankerbestrijding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract